Compass Therapeutics (CMPX) Proxy filing summary

Executive summary

• The 2026 Annual Meeting will be held virtually on June 10, 2026, with voting available online, by phone, or by mail.

• Stockholders of record as of April 15, 2026, are entitled to vote on all matters presented.

• Proxy materials are distributed primarily via Internet to reduce costs and environmental impact.

Voting matters and shareholder proposals

• Election of two Class III directors to serve until the 2029 annual meeting.

• Ratification of CohnReznick LLP as independent auditor for fiscal year ending December 31, 2026.

• Advisory vote on executive compensation (Say-on-Pay).

• Advisory vote on the frequency of future Say-on-Pay votes, with the board recommending annual votes.

• Procedures for submitting shareholder proposals and director nominations for future meetings are outlined.

Board of directors and corporate governance

• The board consists of seven members divided into three staggered classes, with detailed biographies provided for all directors.

• All directors except the CEO are considered independent under Nasdaq and SEC rules.

• The board has Audit, Compensation, and Nominating & Corporate Governance Committees, each with independent members and defined charters.

• Attendance at board and committee meetings exceeded 75% for all directors in 2025.

• Insider trading and code of ethics policies are in place, with prohibitions on short sales and derivatives.